Cytek BioSciences CTKB 深 滬
等待開盤 11-01 09:30:00 美东时间
3.90
+0.080
+2.09%
華盛通- 最 高3.91
- 今 開3.78
- 成交量 48.54万股
- 最 低 3.705
- 昨 收 3.82
- 總市值 4.95亿
- 52周最高 7.30
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 2.37
- 委 比 -63.01%
- 總股本 1.27亿
- 歷史最高 28.70
- 量 比 0.81
- 振 幅 5.37%
- 歷史最低 2.37
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Cytek Biosciences has launched a two-part research initiative in partnership with ISAC to expand access to flow cytometry worldwide. The first phase involves awarding a three-laser Cytek Northern Lights flow cytometer, while the second phase plans to introduce a grant program to fund research projects. These efforts aim to support under-resourced labs and advance global scientific equity, building on previous collaborations like donating equipmen...
10-29 21:00
Cytek Biosciences Announces The Relocation Of Its European Headquarters To A New Facility In Amsterdam's Life Sciences District
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today
10-16 05:04
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Cytek Biosciences, a leader in spectral flow cytometry, will showcase its advanced solutions at the ESCCA 2025 Conference in Montpellier, France, and ICCS 2025 in Philadelphia. The company's Full Spectrum Profiling™ (FSP®) technology has revolutionized cell biology and diagnostics, enabling high-parameter analysis with reduced reagent use and streamlined workflows. At ESCCA, Joseph Lownik, MD, PhD, will present a workshop on integrating spectral ...
09-10 21:00
昆仑资本荣获「年度最佳CVC科技投资机构」等九项荣誉
（来源：昆仑万维（维权）） 昆仑资本由昆仑万维创始人周亚辉先生于2015年创立，专注于科技创新型企业投资，当前已在量子计算、可控核聚变、脑机接口、生物基因...
09-03 18:54
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. announced its participation in several investor conferences, including the UBS Precision Medicine Summit in Dana Point, CA, featuring a panel discussion on August 14; the Wells Fargo Healthcare Conference in Boston, MA, with investor meetings on September 4; and the Morgan Stanley Global Healthcare Conference in New York, NY, hosting a fireside chat on September 10. The company, known for its advanced cell analysis solutio...
08-12 20:05
Cytek Biosciences Earnings Call Reveals Mixed Outlook
Cytek Biosciences, Inc. (($CTKB)) has held its Q2 earnings call. Read on for th...
08-08 09:51
Cytek Biosciences Narrows FY2025 Sales Guidance from $196.000M-$210.000M to $196.000M-$205.000M vs $198.301M Est
Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.000 million vs $198.301 million estimate.
08-07 04:28
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
Cytek Biosciences announced it will release its Q2 2025 financial results after market close on August 6, 2025. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments, and outlook. A live audio webcast will be available on the company’s Investor Relations website. Cytek Biosciences is a leading provider of advanced cell analysis solutions, leveraging its patented Full Spectrum Profi...
07-23 20:05
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
